CANF - התחייבויות לטווח ארוך להון Can-Fite BioPharma

The high scalability of Can-Fite BioPharma (CANF), driven by the global replication of patents, provides potential for superprofits. The ratio of long-term liabilities to equity demonstrates current financial stability, with the parameter stabilizing at 0.00. The business relies on small molecules to combat liver cancer, while the complete non-cyclicality of demand for life-saving medicines guarantees the asset's macro-stability.

Developing proprietary molecules for cancer therapy requires significant long-term funding. This chart reflects Can-Fite BioPharma (CANF) dependence on external borrowings with maturities exceeding one year. The long-term debt-to-equity ratio is calculated by dividing total long-term liabilities by shareholders' equity. A decrease in this ratio indicates growing financial autonomy for the business, while an increase signals potential risks for the investor should the cost of credit resources rise.